Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517075 · ClinicalTrials.gov registry record · Phase 2
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00517075 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 14 participants.
The verdict
NCT00517075, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia. This will be the first rTMS study to assess social function and social cognition. 1. Hypoactivity in the dorsolateral prefrontal cortex (DLPFC) has been implicated in generating the negative symptoms of schizophrenia. Abnormalities in the left inferior parietal lobe (IPL) have also been associated with negative symptoms. We hypothesize that high frequency rTMS applied to the hypoactive left DLPFC or to the left IPL in individuals with schizophrenia will reduce negative symptom severity more than sham (placebo) rTMS as assessed by the Positive and Negative Syndrome Scale (PANSS) negative symptoms subscale. 2. We hypothesize that high frequency rTMS applied to the left DLPFC or to the left IPL in schizophrenia patients will improve social dysfunction more than sham (placebo) rTMS as assessed by the Social Adjustment Scale, the Social Adaptation Self-Evaluation Scale and the Social Functioning Scale.
Interventions
- DEVICE Transcranial Magnetic Stimulation (TMS)
- DEVICE repetitive transcranial magnetic stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517075
The ClinicalTrials.gov registry entry for NCT00517075 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial Magnetic Stimulation (TMS) is the first listed.
NCT00517075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00517075 about?
NCT00517075 is a clinical study titled "Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)". This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia. This will be the first rTMS study to assess social function and social cognition. 1. Hypoactivity in the dorsolateral prefrontal cortex (DL...
What is the current status of trial NCT00517075?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2004-09. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00517075?
The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) (DEVICE), repetitive transcranial magnetic stimulation (DEVICE).
Who is sponsoring clinical trial NCT00517075?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.